Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
5-alpha reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences, Urology and Andrology. Department of Urology, Ryhov County Hospital, 551 85, Jönköping, Sweden.
Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences, Urology and Andrology.
2015 (English)In: Cancer Causes and Control, ISSN 0957-5243, E-ISSN 1573-7225, Vol. 26, no 9, p. 1289-1297Article in journal (Refereed) Published
Abstract [en]

5-alpha reductase inhibitors (5-ARI) have been suggested to increase the risk of male breast cancer. The aim of this study was to study the risk of breast cancer in men on 5-ARI, in men with benign prostatic hyperplasia (BPH) not on 5-ARI, and in men without BPH. We performed a population-based cohort study in Sweden with data from The Prescribed Drug Register, The Patient Register, and The Cancer Register. Men on 5-ARI, men on alpha-blockers, or men who had undergone a transurethral resection of the prostate (TUR-P) prior to or during 2006-2008 were included as exposed to BPH and a specific treatment thereof. For each exposed man, five unexposed men were selected. Risk of breast cancer was calculated in Cox proportional hazard models. There were 124,183 exposed men and 545,293 unexposed men, and during follow-up (median 6 years), 99 men with breast cancer were diagnosed. Compared to unexposed men, men on 5-ARI had a hazard ratio (HR) of breast cancer of 0.74 (95 % confidence interval (CI) 0.27-2.03), men on alpha-blockers had HR 1.47 (95 % CI 0.73-2.95), and men with a TUR-P had HR 1.99 (95 % CI 1.05-3.75). No increased risk of breast cancer was observed for men on 5-ARI. However, the increased risk of breast cancer among men who had undergone a TUR-P, a strong indicator of BPH, suggests that the endocrine milieu conducive to BPH is associated with male breast cancer.

Place, publisher, year, edition, pages
2015. Vol. 26, no 9, p. 1289-1297
Keyword [en]
5-alpha reductase inhibitors, Male breast cancer, Benign prostatic hyperplasia
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-108454DOI: 10.1007/s10552-015-0622-4ISI: 000359941800007PubMedID: 26109464OAI: oai:DiVA.org:umu-108454DiVA, id: diva2:857238
Available from: 2015-09-28 Created: 2015-09-11 Last updated: 2018-06-07Bibliographically approved

Open Access in DiVA

fulltext(756 kB)113 downloads
File information
File name FULLTEXT01.pdfFile size 756 kBChecksum SHA-512
c3383a82c9ba838a87f505db54637df405dd69aade50486a31a5ca5cc47dab7b894d48c81aad36e96e6b8553e7e2bfddbee3674d3a601baf4e32a5b09e10a011
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Robinson, DavidStattin, Pär
By organisation
Urology and Andrology
In the same journal
Cancer Causes and Control
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 113 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 80 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf